Pfizer-BioNTech Reveals Updated Longer-Term Data On COVID-19 Shot In Adolescents

Pfizer Inc PFE and BioNTech SE BNTX have submitted longer-term follow-up data from the Phase 3 trial of the COVID-19 mRNA vaccine in adolescents to the European Medicines Agency (EMA).

  • The data from 2,228 individuals 12 through 15 years of age aims to support further the favorable safety and efficacy profile of Comirnaty in this age group. 
  • In the trial, a two-dose series of Comirnaty (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose. 
  • Related: Pfizer Plans To Evaluate Third Shot For Its COVID-19 Vaccine In Kids Below 5 Years.
  • Among 30 confirmed symptomatic cases of COVID-19 in the trial with and without evidence of prior infection with SARS-CoV-2 were in the placebo group, and no cases were in the Pfizer-BioNTech vaccine group.
  • The adverse event profile was generally consistent with other clinical safety data for the vaccine. After the second dose, a favorable safety profile was observed in individuals with at least six months of safety follow-up. 
  • Price Action: PFE shares are down 1.94% at $58.40, and BNTX stock is down 0.85% at $257.50 during the market session on the last check Thursday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!